International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 08 Issue: 12 | Dec - 2024 SJIF Rating: 8.448 ISSN: 2582-3930

Echoes of Pain: Unraveling the Mystery of Migraines

Tanu Jain[1st], Himanshi Bains[2nd], Gurprasad Singh[3rd], Shahab Ahmad[4th], Gunjot Singh[5th], Harsimrat Kaur[6th], Jagjeet Singh[7th], Anchal Dhawan[8th]

ABSTRACT

A complex and disruptive neurological illness, migraines are marked by frequent, severe headache episodes that are frequently accompanied by phonophobia, photophobia, and nausea. Despite their frequent occurrence, effective therapy is difficult because of the incomplete understanding of the root causes. This study looks at the neurovascular, genetic, and environmental elements that contribute to the pathophysiology of migraines to better understand their complex character. We review current hypotheses, such as the involvement of neurotransmitters and the central nervous system's reaction to pain, as well as cortical spreading depression and neuro inflammation. Additionally, we evaluate improvements in therapy strategies, including both non-pharmacological and pharmaceutical therapies, as well as diagnostic criteria. Through the integration of these various components, this article aims to present a thorough review of migraine research, identify current knowledge gaps, and suggest future lines of study, eventually advancing better management techniques for those who experience this illness.

INTRODUCTION

A very common neurological condition, migraine is characterized by painful, frequent headaches that are frequently accompanied by light and sound sensitivity, nausea, and vomiting. It has a major negative influence on the quality of life for people who are impacted and is one of the main causes of disability globally. The exact cause of migraines is still not entirely known despite a great deal of research. The purpose of this review is to examine the most recent developments in the understanding of the mechanisms for migraine, the effectiveness of available treatments, and new therapeutic approaches. We want to present a thorough summary of the state of migraine research today and identify possible directions for further study by looking at molecular markers, imaging methods, and clinical trials.

MIGRAINE

The International Headache Society's diagnostic criteria state that a patient must have experienced at least five 4 to 72 hours (about 6 days) headache attacks with at least two of the following features to be diagnosed with migraine disease:

- One-sided positioning
- Pulsating quality
- Intensity of pain: mild to severe
- aggravated by or leading to an avoidance of routine physical activity

Furthermore, the patient needed to have experienced at least one of the following throughout the headache:

- vomiting and/or nausea
- photophobia and phono phobia

Migraine is a complex neurological disease with the symptoms beyond a headache. It can impact the entire nervous system. This means people may experience symptoms in various parts of the body. Here are some migraine symptoms that aren't often associated with migraine:

- Imbalance
- Difficulty in speaking
- Sinus pain
- Poor sleep
- Anxiety

MIGRAINE PHASES

There are various stages that migraine attacks can go through, each having their own distinctive symptoms that vary in intensity and duration. Though it appears in this graph as four separate periods, there is a lot of overlap in the symptoms. Not everyone goes through all four stages, and attacks might differ from person to person. The prodrome and postdrome stages of a migraine attack are distinctive. Even though person might not be experiencing a headache at this point, but they might not feel or function well for several hours or even days. A prodrome for many migraine patient is the beginning of yawning or depressive, fatigue, or tired emotions. The interictal phase is the name for a fifth phase that occurs between cycles. It can take an erratic amount of time and as a result, some suffer with the fear of not knowing when they will have another attack.



Migraine with aura:

There are now two basic types of migraine recognized: migraine with aura and migraine without aura. A brief sensory disturbance that occurs prior to or during a headache is called an aura. Common auras include the appearance of altered eyesight, a disagreeable phantom odor, or disoriented thought processes. Visual auras are by far the most prevalent, though patients also describe an aura where they experience numbness that starts in an extremity and spreads centrally. A scintillating scotoma, or a small central patch of temporary blindness followed by highly colored, shimmering light, is the "classic" visual aura. It's important to keep in mind that not all headaches must cause an aura, and roughly 5% of people who have an aura never experience a headache. An ophthalmic, or ocular, migraine is the most frequent type of these mild migraine episodes. This is frequently misdiagnosed as a stroke or transient ischemic attack (TIA).

Chronic versus episodic migraine:

People with migraine who have 0 to 14 headache days per month are said to have episodic migraine, whereas those with chronic migraine must experience 15 or more headache days per month and 8 or more days of "migraine-like features."

ESTABLISHED TYPES:

Vestibular Migraine:

It might not be long until this ailment is identified as the primary cause of dizziness. Its broad spectrum of symptoms (including tinnitus, spinning, ear pressure, and imbalance) as well as its variable duration (ranging from seconds to days) set it apart from other headache-related symptoms like blurred vision, intolerance to bright lights and noises, neck pain and spasms, disorientation, confusion, and elevated anxiety. It mimics Meniere's disease and benign positional vertigo, the other two major balance disorders. Vestibular migraine is now recognized as a separate category of migraine in the most recent edition of the International Classification of Headache Disorders.

Epidemiology:

- 1-year prevalence: 0, 9-3, 2%
- Vertigo/ dizziness in 9-47,5% patients with migraine
- F>M(1,5-5X)
- Can occur at any age

Pathophysiology:

Inherited brain excitability sensation **trigeminal-vascular reflex**



Treatment:

- migraine
- Zolmitriptan DOC for acute attack
- Migraine prophylaxis
- Vestibular rehabilitation training

Ocular migraine:

An ocular migraine is an episode that can last up to an hour and normally affects only one eye. During this time, any number of visual abnormalities might happen. Although the major reason is believed to be constriction or enlargement of the blood vessels in the optic nerve located in the rear of the eye, there might be additional causes involved as well. A blind spot in the center of vision is frequently the first sign of an attack, and it can start tiny and grow larger. This is frequently followed by an aura stage, which may include further visual distortions like a kaleidoscope view or what appears to be a spot of light traveling throughout your central and peripheral vision. An ocular migraine attack may or may not be accompanied by a headache.

Risk factors and causes include

- similar causes and risk factors for migraines.
- Most common in women
- Age varies from 30-39
- Family history.

Symptoms

- A blind spot in the central area of vision
- Lasts less than 60 minutes
- Seen in one eye
- Can also affects the peripheral vision.

Treatment

- Severe: Doctor's prescription
- Mild: OTC medication like acetaminophen, ibuprofen, naproxen.

Hemiplegic migraine:

A person with hemiplegic migraine (HM), an uncommon kind of migraine, suffers motor weakness on one side of their body. Usually, this is accompanied by or follows a headache. A type of aura known as weakness is accompanied by at least one additional aura symptom, such as alterations in vision. The weakness can range in severity from mild to severe and is not usually on the same side as the headache. Only a portion of the body, such as the hand, the arm, or the face, may be affected by HM. It is possible for one side to suffer from regular aura migraine bouts (without weakness).

Familial hemiplegic migraine has been linked to abnormal mutations in three genes. Familial HM type 1 is brought on by variations in the CACNA1A gene. Familial HM type 2 is caused by mutations in the ATP1A2 gene. Familial HM type 3 is brought on by variations in the SCN1A gene. the body to become weak. Seizures, a loss of consciousness, or a coma may ensue after severe episodes of HM.



Migraine with brainstem:

Formerly known as basilar migraine, migraine with brainstem aura is a subtype of migraine. This diagnosis is not without disagreement, and different sources have different statistics on how common it is and what causes/origin.

This kind of migraine happens when there is no accompanying motor weakness, yet the aura symptoms are of the kind that are assumed to come from the brainstem. A migraine with aura that includes at least two of the following symptoms is MBA, according to the ICHD-3. These symptoms include vertigo, ringing in the ears, partial hearing loss, diplopia, impaired coordination, ataxia, or a decreased level of consciousness.

Symptoms

- Visionary changes
- Viewing static or zigzag lights
- Sensitivity to light
- Numbness in face, head and hands
- Vertigo
- Impaired hearing
- Double vision
- Depression
- Tingling effect
- Hyperventilation

Causes

- Stress
- Caffeine
- Alcohol and prolonged hunger
- Motion sickness
- Bright lights
- Strong odor
- Hormonal imbalance
- Seizures or epilepsy

Treatment

- Doctors prescription: NSAIDS(Ibuprofen) + antiemetic to combat vomiting and nausea
- Seizure reducing medication (topiramate)
- Verapamil (isoptin) lowering blood pressure
- Lifestyle modification: regular exercise, balanced diet, regular sleep, reducing noise exposure.

Silent migraine:

When a person gets a migraine without experiencing head pain, they go through all the phases of the migraine, including the aura phase. In addition to nausea, visual abnormalities, runny nose, dizziness, weakness, and brain fog, migraineurs without head pain may also have other symptoms.



Abdominal migraine:

Recurrent episodes of moderate to severe abdominal pain accompanied by nausea in children, with or without vomiting, are the hallmark of abdominal migraine. There is frequently no accompanying headache. Between attacks, there are no symptoms for two to three days. Migraineurs Status: A migraine that lasts longer than 72 hours (about 6 days) is referred to as status migraines, commonly known as an intractable migraine. The sensations are more intense than those of a regular migraine and trying to treat them with medicine usually doesn't work. Treatment for this extremely difficult-to-treat condition may require hospitalization for pain management and to prevent dehydration.

Symptoms and causes

- Appetite loss
- Nausea and vomiting
- Headache
- Pale appearance

Triggers

- Irregular sleep
- Stress and depression
- Dehydration
- Fasting for long hours
- Travel or motion sickness
- High amine foods such as citrus fruits, chocolates, cheese, ham
- Foods with preservatives and coloring agents
- Excessive caffeine consumption

Treatment

- Pizotifen
- Cyproheptadine
- Flunarizine
- Propranolol
- NSAIDS
- Anti-nausea medication
- Triptans (serotonin receptor antagonist).

Sinus migraine:

More than 80% of individuals who were presented with sinusitis also fit the criteria for migraine illness, according to a study. The trigeminal-autonomic reflex is thought to be the source of sinus-like symptoms, such as mid-facial pain, stuffy nose, nasal discharge, and loss of smell. When sinus-like symptoms are combined with the ICHD-3 migraine diagnostic criteria, sinus migraine is most likely the cause of the symptoms. Before determining that a patient has sinusitis, it is crucial for medical professionals to screen for migraines. Usually, sinus diseases are ruled out before sinus migraine is diagnosed. Misdiagnosis of these related illnesses can result in overuse of antibiotics and avoidable surgery.



Pathophysiology of migraine

Migraine pathophysiology is multifactorial, involving neurological, vascular, and hereditary components. Below is a summary of the main procedures:

1. Genetic and environment Predisposition:

Migraine susceptibility may be increased by specific genetic mutations.

Environmental Factors: A migraine can be brought on by a variety of triggers, including stress, hormone shifts, particular foods, and environmental factors like bright lights and strong smells.

2. Depression with Cortical Spreading (CSD):

Onset: The brain's cortical surface experiences a surge of electrical activity. Cortical spreading depression is the term for this.

Depolarization: Cortical neurons experience a quick, sharp depolarization that is followed by a protracted refractory phase.

3. Release of Neuropeptides:

Calcitonin Gene-Related Peptide (CGRP): This substance widens blood arteries by stimulating vasodilation, and it is released during CSD.

Substance P: The release of another neuropeptide that has a role in neurogenic pain and inflammation.

4. Inflammation Caused by Neurogenesis

Vasodilation: The brain and the tissues around it experience a dilatation of blood vessels.

Enhanced Permeability: Inflammatory mediators can pass across the blood-brain barrier and into the brain tissue.

Pain Receptor Activation: When pain receptors (nociceptors) are sensitized by inflammation, pain perception is enhanced.

5. Activation of the Trigeminal Nerve

Trigeminal Nerve: One of the main pain pathways in the face and head is the trigeminal nerve.

The trigeminal system becomes more sensitive to stimuli when it experiences central sensitization. This involves heightened awareness and a lowered pain threshold.

6. Sensitization of the Center

Enhanced Pain Sensitivity: The central nervous system's neurons become hyperexcited and more pain-sensitive.

Pain sense: Even with mild stimuli, this increased sensitivity results in an amplified sense of pain.

7. Anxiety Routes

Thalamus: The thalamus receives pain signals and analyzes them before forwarding the information to the cortex.

Cortex: The cortical regions in charge of processing pain interpret the pain as a headache.

8. Phases of Migraine

Prodrome: Ahead of time symptoms that manifest hours to days in front of headache, such as mood swings, exhaustion, or food cravings.

Aura (occasionally): neurological abnormalities that manifest either prior to or during the headache, such as impairments in vision or sensory experiences.

Headache: The actual migraine attack, which is marked by intense, pulsating pain that is frequently unilateral and is accompanied by light and sound sensitivity and nausea.

Postdrome: Following a headache, people may continue to feel tired or have mood swings.

9. Resolution Recovery Phase

Although the person may still feel fatigued or have some lingering symptoms, the headache gradually goes away and they resume their normal state.

Recognizing how genetics, brain alterations, and inflammatory processes interact to cause and worsen migraine attacks is essential to understanding the pathophysiology of migraines.

Migraine pathogenesis



Causes and Triggers:

Although the precise etiology of migraines is still unknown, a combination of neurological, environmental, and genetic variables is thought to be the reason. Changes in brain circulation, especially in regions of the brain involved in pain processing, are thought to have a role in migraines.

There are numerous factors that might cause a migraine, such as:

- Hormonal Changes: Menstrual, pregnancy, or menopausal hormone variations can cause migraines, especially in women.

- Dietary factors: Certain foods and drinks, such as aged cheeses, coffee, alcohol, and meals high in MSG or nitrates, can act as triggers.
- Stress: One well-known trigger is stress, either physical or emotional.
- Sensory Stimuli: Excessive loudness, bright lights, or potent scents can all cause migraines.
- Sleep Patterns: Excessive or insufficient sleep can act as a trigger.
- Variations in the weather: Weather changes such as humidity and barometric pressure can trigger migraine.

SYMPTOMS:

Migraine usually has four phases, but a person might not experience all the phases:

Prodrome: Occurs a few days or hours prior to a headache. Changes in mood, food cravings, and exhaustion are among the symptoms.

Aura: This stage comes 20–60 minutes before headaches and may include tingling feelings, speech difficulty, or visual impairments (such as seeing flashes of light or blind patches).

Headache: A throbbing pain that usually affects one side of the head is the hallmark of a headache. In addition to the often-present nausea, vomiting, and light and sound sensitivity, the pain can be quite intense.

Postdrome: Following the headache, people may feel worn out or tired and find it difficult to focus.

TREATMENT AND MANAGEMENT:

- Medications, dietary adjustments, and complementary therapies are frequently used together for effective migraine treatment:
- Medication: This category includes both preventative (which lowers the frequency and intensity of migraines) and acute (which relieves symptoms during a migraine) medications. NSAIDs, anti-nausea medicines, and triptans are common acute treatments. Antidepressants, beta-blockers, and anticonvulsants are examples of preventive measures.
- Lifestyle Changes: Frequent exercise, a regular sleep pattern, and stress reduction methods can all help lessen the frequency of migraine attacks. It's critical to recognize and stay away from personal triggers.
- Dietary Modifications: It can be helpful to keep a food journal to recognize and avoid triggering foods.
- Alternative Therapies: Acupuncture, biofeedback, and cognitive-behavioral therapy are effective for certain people.

The management of migraine begins with the explanation of certain things to the patient:

- Migraine inherits cerebral functioning and cannot be cured
- Migraine can be treated by lifestyle modification and medications
- Migraine is not at all a serious illness or life threatening.

MEDICATIONS

Abortive medications:

- Analgesics with caffeine (PCM, acetaminophen, aspirin, caffeine)
- Analgesics with caffeine and barbiturates
- Non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen, naproxen
- Triptans
- Antiemetics

Preventive medications:

-Beta blockers

-Calcium channel blockers

-Antidepressants

-Anticonvulsants

-NSAIDs

ORAL OPTIONS IN ACUTE MANAGEMENT

NON- SPECIFIC TREATMENTS:

-Aspirin (900 mg)

-Paracetamol (1000 mg)

-NSAIDs:

Naproxen (500-1000 mg)

Ibuprofen (400-800 mg)

Tolfenamic acid (200 mg)

SPECIFIC TREATMENTS

ERGOT DERIVATIVES: -

ERGOTAMINE (1-2 MG)

TRIPTANS: -

Sumatriptan (50 or 100 mg)

Zolmitriptan (2.5 or 5 mg)

Naratriptan (2.5 mg)

Rizatriptan (5 or 10 mg)

Almotriptan (12.5 mg)

Eletriptan (40 or 80 mg)

Frovatriptan (2.5 mg)

COMPARISON OF AVAILABLE TRIPTANS:

DRUG	TIME TO PEAK LEVELS	ELIMINATION HALF LIFE(HRS)	BIOAVAILABILITY	CLINICAL USE
Sumatriptan	12 min 2-3 hours	2	97 14	SC for rapid onset attack SC/NS with nausea and vomiting
Rizatriptan	1 hour 1-2 hour	2	40-50	ODT for nausea and vomiting
Zolmitriptan	1-1.5 hour 3 hours 2 hours	2.5-3	40-50	ODT/NS for nausea and vomiting
Almotriptan	1.5 hours	3.5	70	Previous adverse effects
Eletriptan	1.5-2 hours	4	50	
Naratriptan	2-3 hours	6	60-70	Long lasting attacks
frovratriptan	2-4 hours	26	20-40	Long lasting attacks

DIAGNOSIS:

A physical examination and assessment of medical history are usually required for migraine diagnosis. The International Headache Society's standards for diagnostic criteria are used by neurologists or primary care physicians. Image tests such as CT or MRI scans are performed to rule out other disorders.


MIGRAINE DIAGNOSIS
PATIENT EDUCATION ASSESSMENTOF SEVERITY
MILD TO MODERATE
ASSOCIATED WITH NAUSEA, VOMITING, DIARRHEA
SEVERE
SIMPLE ANALGESICS
ADD AN ANTIEMETIC
TRITANS
DHE NASAL SPRAY
COMBINATION ANALGESICS & CAFFEINE
INADEQUATE RESPONSE
BUTORPHANOL NASAL SPRAY
INADEQUATE RESPONSE
CONSIDER PREVENTIVE THERAPY
CORTICOSTEROIDS
MANAGE AS SEVERE MIGRAINE

CONCLUSION:

In conclusion, migraine is still a complicated neurological condition with many facets that has a big impact on both public and individual health. Although the underlying mechanisms have been clarified by recent scientific developments, many elements of its pathophysiology are still unclear. Some people find relief from current treatment options, but more efficient and focused therapies are constantly needed. Understanding the complex nature of migraines requires ongoing and upcoming research concentrating on genetic, molecular, and environmental components. We are able to reduce the impact of migraine for millions of people globally by promoting a greater knowledge and investigating cutting-edge therapeutic approaches.

REFERENCES:

1. www.migrainedisorders.org/migraine-disorders/
2. link.springer.com
3. www.mdpi.com
4. www.frontiersin.org
5. Vestibular migraine by Ade Wijeya, MD-2018
6. www.aoa.org
7. www.verywell.com
8. Health & medicine slide share by Harsh shah
9. Pleș et al1. (2023). "Migraine: Advances in the Pathogenesis and Treatment." Neurology International, 15(3), 1052-11051.
10. Puledda et al3. (2023). "Migraine: from pathophysiology to treatment." Journal of Neurology, 270, 3654-36663.
11. Zobdeh et al4. (2021). "Advances in understanding migraine pathophysiology: a bench to bedside approach." Frontiers in Molecular Neuroscience, 15, 1355281
12. National Institute of Neurological Disorders and Stroke
    Provides information about migraines, including the causes of the pain and common symptoms
13. StatPearls - NCBI Bookshelf
    Discusses migraines with aura, including the symptoms and phases of a migraine attack
14. Mayo Clinic
    Provides information about migraines, including symptoms, causes, and treatments
15. Radiopaedia.org
    Provides a radiology reference article on migraines
16. BMJ Best Practice
    Provides reference articles on migraines, including "Migraine: diagnosis and treatment" by Silberstein SD, Saper JR, and Freitag F
17. NCBI Bookshelf
    Provides information on migraine medications, including lasmiditan and CGRP monoclonal antibodies

18. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343–9. doi: 10.1212/01.wnl.0000252808.97649.21. PMID: 17261680. [PubMed] [CrossRef]

19. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2017 Jan 5;388(10053):1545–602. doi: 10.1016/S0140-

6736(16)31678-6. PMID: 27733282. [PMC free article] [PubMed] [CrossRef]

20. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81–92. doi: 10.1111/j.1526-4610.2012.02265.x. PMID: 23078241. [PubMed] [CrossRef]

21. Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821–34. doi: 10.1111/head.12774. PMID: 27143127. [PMC free article] [PubMed] [CrossRef]

22. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache: The Journal of Head and Face Pain. 2002;42:3–9. [PubMed]

23. Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778–93. doi: 10.1111/head.12550. PMID: 25877672. [PubMed] [CrossRef]

24. Lipton RB, Schwedt TJ, Friedman BW, et al. Demographics, Headache Characteristics, and Other Factors Associated With Opioid Use in People With Migraine: Results From the CaMEO Study (S59. 006). AAN Enterprises; 2019.

25. Lipton R, Araujo A, Nicholson R, et al. Patterns of Diagnosis, Consultation, and Treatment of Migraine in the US: Results of the OVERCOME Study [abstract]. 61st Annual Scientific Meeting American Headache Society® 2019 July 11 -14 2019; Pennsylvania Convention Center Philadelphia, PA. HEADACHE; 59. pp. 2–3.

26. Ashina S, Foster S, Nicholson R, et al. Opioid Use Among People with Migraine: Results of the OVERCOME Study [abstract]. 61st Annual Scientific Meeting American Headache Society® 2019 July 11 -14 2019; Pennsylvania Convention Center Philadelphia, PA. HEADACHE; 59. pp. 11-.

27. Molina KC, Fairman KA, Sclar DA. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthc Patient Saf. 2018;10:37–43. doi: 10.2147/DHPS.S151073. PMID: 29760569. [PMC free article] [PubMed] [CrossRef]

28. Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019 Aug;39(9):1086–98. doi: 10.1177/0333102419835465. PMID: 30818974. [PubMed] [CrossRef]

29. Connelly M, Glynn EF, Hoffman MA, et al. Rates and Predictors of Using Opioids in the Emergency Department to Treat Migraine in Adolescents and Young Adults. Pediatr Emerg Care. 2019 Jun 22. doi: 10.1097/PEC.0000000000001851. PMID: 31246788. [PubMed] [CrossRef]

30. Vinson DR, Hurtado TR, Vandenberg JT, et al. Variations among emergency departments in the treatment of benign headache. Ann Emerg Med. 2003 2003/01/01/;41(1):90–7. doi: 10.1067/mem.2003.24. [PubMed] [CrossRef]

31. Charleston Iv L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018 Apr;38(5):876–82. doi: 10.1177/0333102417716933. PMID: 28649860. [PubMed] [CrossRef]

32. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3–20. doi: 10.1111/head.12499. PMID: 25600718. [PubMed] [CrossRef]

33. Skelly AC, Chou R, Dettori JR, et al. AHRQ Comparative Effectiveness Reviews. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020. [PubMed]

34. Chen L-C, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache. 2007 Sep;47(8):1169–77. PMID: 17883521. [PubMed]

35. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2012 Feb 15(2):CD008615. PMID: 22336849. [PMC free article] [PubMed]

36. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia. 2005 Sep;25(9):715–25. PMID: 16109054. [PubMed]

37. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther. 2005 Dec;30(6):521–32. PMID: 16336284. [PubMed]

38. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2013 Oct 21(10):CD008541. PMID: 24142431. [PubMed]

39. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2013 Oct 21(10):CD008541. PMID: 24142431. [PubMed]

40. Xu H, Han W, Wang J, et al. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016 Dec;17(1):113. doi: 10.1186/s10194-016-0703-0. PMID: 27957624. [PMC free article] [PubMed] [CrossRef]

41. Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther. 2007 Jul;29(7):1441–7. PMID: 17825695. [PubMed]

42. Amiri H, Ghodrati N, Nikuyeh M, et al. Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: A randomized controlled trial study. Turk J Emerg Med. 2017 Jun;17(2):61–4. PMID: 28616617. [PMC free article] [PubMed]

43. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011 Apr;51(4):507–17. PMID: 21457235. [PubMed]

44. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009 Jun;49(6):826–37. PMID: 19545249. [PubMed]

45. Avcu N, Dogan NO, Pekdemir M, et al. Intranasal Lidocaine in Acute Treatment of Migraine: A Randomized Controlled Trial. Ann Emerg Med. 2017 Jun;69(6):743–51. PMID: 27889366. [PubMed]

46. Banerjee M, Findley L. Propranolol in the treatment of acute migraine attacks. Cephalalgia. 1991 Sep;11(4):193–6. PMID: 1742775. [PubMed]

47. Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990 Oct;19(10):1079–82. PMID: 2221511. [PubMed]

48. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache. 2002 Oct;42(9):862–71. PMID: 12390611. [PubMed]

49. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002 Aug;23(2):141–8. PMID: 12359281. [PubMed]

50. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002 Jun;22(5):345–53. PMID: 12110110. [PubMed]

51. Blanda M, Rench T, Gerson LW, et al. Intranasal lidocaine for the treatment of migraine headache: a randomized, controlled trial. Acad Emerg Med. 2001 Apr;8(4):337–42. PMID: 11282668. [PubMed]

52. Borhani Haghighi A, Motazedian S, Rezaii R, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010 Mar;64(4):451–6. PMID: 20456191. [PubMed]

53. Boureau F, Joubert JM, Lasserre V, et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994 Apr;14(2):156–61. PMID: 8062355. [PubMed]

54. Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019 Aug 21:333102419864132. PMID: 31433669. [PMC free article] [PubMed]

55. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26(4):168–71. PMID: 17199220. [PubMed}.